Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYRO3 | Q06418 | 2/20 | 0.61 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.61 |
| ▸ | PDE3B | Q13370 | 16/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 16/20 | 0.47 |
| ▸ | PRKD3 | O94806 | 2/20 | 0.43 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.43 |
| ▸ | RET | P07949 | 2/20 | 0.43 |
| ▸ | PIM1 | P11309 | 2/20 | 0.43 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | GSK3A | P49840 | 2/20 | 0.43 |
| ▸ | GSK3B | P49841 | 2/20 | 0.43 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.43 |
| ▸ | MAP4K2 | Q12851 | 2/20 | 0.43 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | PAK4 | O96013 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10400997 | 0.77 | ALDH1A1 (0.50) | TYRO3DYRK1BKDRRPS6KA3 | |
| SCHEMBL29502006 | 0.76 | TYRO3 (1.00) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL18168235 | 0.76 | TYRO3 (1.00) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL31465446 | 0.76 | TYRO3 (0.61) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL29488789 | 0.76 | TYRO3 (0.61) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL28671355 | 0.76 | TYRO3 (0.56) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL18238554 | 0.76 | TYRO3 (0.56) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL26160854 | 0.76 | TYRO3 (0.56) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL26017865 | 0.76 | TYRO3 (0.56) | TYRO3DYRK1BPDE3BPDE3APRKD3 | |
| SCHEMBL31139261 | 0.74 | TYRO3 (0.54) | TYRO3DYRK1BPDE3BPDE3APRKD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| EP-4180434-A1 | PB2 INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Haisco Pharmaceutical Co., Ltd. (CN) | 2023-05-17 | — | — | EP | disclosed |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022177302-A1 | PYRIMIDINE-FUSED RING COMPOUND WITH DNA-PK INHIBITION ACTIVITY AND USE THEREOF | 보령제약 주식회사 | 2022-08-25 | — | — | WO | disclosed |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2021-11-02 | — | — | US | disclosed |
| US-20200079776-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2020-03-12 | — | — | US | disclosed |
| US-10399980-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-09-03 | — | — | US | disclosed |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | FORMA THERAPEUTICS, INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180339986-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2018-11-29 | — | — | US | disclosed |
| EP-3377493-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | Forma Therapeutics, Inc. (US) | 2018-09-26 | — | — | EP | disclosed |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | BLINKBIO, INC. | 2017-07-20 | — | — | US | disclosed |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | FORMA THERAPEUTICS, INC. | 2017-05-25 | — | — | US | disclosed |
| US-8946257-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | VECTURA LIMITED (GB) | 2015-02-03 | — | — | US | disclosed |
| CN-103649085-A | Pyridin-2(1h)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases | ALMIRALL SA | 2014-03-19 | — | — | CN | disclosed |
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | PALAU PHARMA, S.A. | 2013-10-31 | — | — | US | disclosed |
| US-8501735-B2 | N-containing heteroaryl derivatives as JAK3 kinase inhibitors | PALAU PHARMA, S.A. (ES) | 2013-08-06 | — | — | US | disclosed |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | VECTURA LIMITED (GB) | 2013-05-23 | — | — | US | disclosed |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | ALMANSA ROSALES CARMEN (ES) | 2012-09-27 | — | — | US | disclosed |
| EP-2358710-B1 | AKT AND P70 S6 KINASE INHIBITORS | LILLY CO ELI (US) | 2012-08-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289015-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | TYRO3 39/4885DYRK1B 1198/4885PDE3B 2171/4885 |
| US-11161848-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
| US-20120245140-A1 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | TYRO3 39/4885DYRK1B 1198/4885PDE3B 2171/4885 |
| US-20180339986-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
| US-20170202970-A1 | SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME | CD44, MSN, AS3MT | TYRO3 1424/4885DYRK1B 1207/4885PDE3B 4693/4885 |
| US-10189841-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
| US-20130131038-A9 | N-CONTAINING HETEROARYL DERIVATIVES AS JAK3 KINASE INHIBITORS | JAK3, JAK2, JAK1 | TYRO3 39/4885DYRK1B 1198/4885PDE3B 2171/4885 |
| US-20200079776-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
| US-10399980-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
| US-20170145012-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
| US-20220281869-A1 | PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
| US-12043623-B2 | Purinones as ubiquitin-specific protease 1 inhibitors | USP1, UBA1, UBXN1 | TYRO3 4289/4885DYRK1B 3503/4885PDE3B 1951/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.